Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
作者信息
Phillips Elizabeth, Bartlett John A, Sanne Ian, Lederman Michael M, Hinkle John, Rousseau Franck, Dunn David, Pavlos Rebecca, James Ian, Mallal Simon A, Haas David W
出版信息
J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55-7. doi: 10.1097/QAI.0b013e31827ca50f.
Abstract
摘要
相似文献
1
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.在南非，含奈韦拉平治疗方案起始阶段，HLA-DRB1*0102、HLA-B*5801与肝毒性之间的关联。
J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55-7. doi: 10.1097/QAI.0b013e31827ca50f.
2
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.奈韦拉平相关肝毒性的药物遗传学：成人艾滋病临床试验组合作项目
Clin Infect Dis. 2006 Sep 15;43(6):783-6. doi: 10.1086/507097. Epub 2006 Aug 15.
3
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.药物转运体和代谢酶基因变异与非核苷类逆转录酶抑制剂肝毒性
Clin Infect Dis. 2006 Sep 15;43(6):779-82. doi: 10.1086/507101. Epub 2006 Aug 15.
4
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.奈韦拉平诱导的肝毒性与药物遗传学：莫桑比克人群的回顾性研究。
Pharmacogenomics. 2010 Jan;11(1):23-31. doi: 10.2217/pgs.09.142.
5
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.含奈韦拉平治疗方案相关严重肝脏事件分析：丙型肝炎血清学阳性和血清学阴性患者的CD4 + T细胞计数及性别
Drug Saf. 2007;30(12):1161-9. doi: 10.2165/00002018-200730120-00008.
6
Pharmacogenetics of antiretrovirals.抗逆转录病毒药物的药物遗传学。
Antiviral Res. 2010 Jan;85(1):190-200. doi: 10.1016/j.antiviral.2009.09.001. Epub 2009 Sep 8.
7
Pharmacogenetic screening: HLA-B(*) 5701 vs. CYP2B6 G516T.药物遗传学筛查：HLA - B(*)5701与CYP2B6 G516T
HIV Med. 2011 Apr;12(4):255-6. doi: 10.1111/j.1468-1293.2010.00870.x.
8
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.抗逆转录病毒初治 HIV 感染成人中含奈韦拉平方案的毒性、血药谷浓度和治疗结局的药物遗传学：TRIANON ANRS 081 试验的探索性研究。
Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):513-20. doi: 10.1111/j.1742-7843.2011.00780.x. Epub 2011 Sep 6.
9
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.CYP2B6基因变异与HIV-1感染儿童的奈韦拉平药代动力学及临床反应相关。
AIDS. 2007 Oct 18;21(16):2191-9. doi: 10.1097/QAD.0b013e3282ef9695.
10
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.CYP2B6基因983T>C多态性对HIV感染患者非核苷类逆转录酶抑制剂血浆浓度的影响。
J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.
引用本文的文献
1
Liver Damage During Treatment with Reverse-Transcriptase Inhibitors in HIV Patients.HIV患者接受逆转录酶抑制剂治疗期间的肝损伤
Curr Health Sci J. 2024 Apr-Jun;50(2):181-197. doi: 10.12865/CHSJ.50.02.03. Epub 2024 Jun 30.
2
Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics.药物基因组学中的人类白细胞抗原（HLA）检测
Methods Mol Biol. 2022;2547:21-45. doi: 10.1007/978-1-0716-2573-6_2.
3
Research Progress of Pharmacogenomics in Drug-Induced Liver Injury.药物基因组学在药物性肝损伤中的研究进展
Front Pharmacol. 2021 Sep 6;12:735260. doi: 10.3389/fphar.2021.735260. eCollection 2021.
4
Progress in study on the association between HLA genetic variation and adverse drug reactions.HLA 遗传变异与药物不良反应相关性研究进展。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Apr 28;46(4):404-413. doi: 10.11817/j.issn.1672-7347.2021.200256.
5
Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice.药物性肝损伤（DILI）中的氧化应激：从机制到临床实践中使用的生物标志物
Antioxidants (Basel). 2021 Mar 5;10(3):390. doi: 10.3390/antiox10030390.
6
Mechanistic insights into antiretroviral drug-induced liver injury.抗逆转录病毒药物性肝损伤的机制研究。
Pharmacol Res Perspect. 2020 Aug;8(4):e00598. doi: 10.1002/prp2.598.
7
Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.人类白细胞抗原多态性与人类免疫缺陷病毒患者对抗逆转录病毒治疗过敏反应的关联：一项荟萃分析。
BMC Infect Dis. 2019 Jul 5;19(1):583. doi: 10.1186/s12879-019-4227-5.
8
Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes.对南非班图语人群进行靶向超深度测序，全面绘制和描述 65 个与药理学相关基因中的常见和新型变异。
Pharmacogenet Genomics. 2019 Sep;29(7):167-178. doi: 10.1097/FPC.0000000000000380.
9
Drug hypersensitivity in HIV infection.HIV 感染中的药物过敏反应。
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):272-282. doi: 10.1097/ACI.0000000000000545.
10
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.新型遗传和表观遗传因素对药物处置、反应和毒性的个体间差异具有重要意义。
Pharmacol Ther. 2019 May;197:122-152. doi: 10.1016/j.pharmthera.2019.01.002. Epub 2019 Jan 22.
本文引用的文献
1
HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity.HLA I类限制性CD8⁺T细胞和II类限制性CD4⁺T细胞与奈韦拉平超敏反应的发病机制有关。
AIDS. 2014 Aug 24;28(13):1891-901. doi: 10.1097/QAD.0000000000000345.
2
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.奈韦拉平相关皮肤和肝脏不良事件的毒代动力学在非洲、亚洲和欧洲血统人群中的研究。
AIDS. 2011 Jun 19;25(10):1271-80. doi: 10.1097/QAD.0b013e32834779df.
3
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.HLA - B*3505等位基因是HIV感染的泰国患者中奈韦拉平诱导的皮肤药物不良反应的强预测指标。
Pharmacogenet Genomics. 2009 Feb;19(2):139-46. doi: 10.1097/FPC.0b013e32831d0faf.
4
HLA-Cw8 primarily associated with hypersensitivity to nevirapine.HLA - Cw8主要与对奈韦拉平的超敏反应相关。
AIDS. 2007 Jan 11;21(2):264-5. doi: 10.1097/QAD.0b013e32801199d9.
5
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.奈韦拉平相关肝毒性的药物遗传学：成人艾滋病临床试验组合作项目
Clin Infect Dis. 2006 Sep 15;43(6):783-6. doi: 10.1086/507097. Epub 2006 Aug 15.
6
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.撒丁岛HIV患者中对奈韦拉平的HLA依赖性超敏反应。
AIDS. 2006 Aug 1;20(12):1621-6. doi: 10.1097/01.aids.0000238408.82947.09.
7
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.HLA - B*5801等位基因作为别嘌醇引起严重皮肤不良反应的遗传标志物。
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9. doi: 10.1073/pnas.0409500102. Epub 2005 Mar 2.
8
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.在感染HIV的受试者中使用奈韦拉平所导致的严重肝毒性。
J Infect Dis. 2005 Mar 15;191(6):825-9. doi: 10.1086/428093. Epub 2005 Feb 10.
9
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.与HLA - DRB1*0101相关的奈韦拉平超敏反应易感性，并因低CD4 T细胞计数而消除。
AIDS. 2005 Jan 3;19(1):97-9. doi: 10.1097/00002030-200501030-00014.
10
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.HLA-B*5701、HLA-DR7和HLA-DQ3的存在与对HIV-1逆转录酶抑制剂阿巴卡韦的超敏反应之间的关联。
Lancet. 2002 Mar 2;359(9308):727-32. doi: 10.1016/s0140-6736(02)07873-x.
Zotero 插件